Physician profile
Mark Vinas
NPI 1952982332
$7,957.20
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.65 · 2022: $5,046 · 2023: $2,879 · 2024: $15.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196 · Travel and Lodging: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.98 |
| Travel and Lodging | $697.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,843.30 | 2022-2023 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Medtronic, INC. | $2,681.01 | 2022-2024 | Synchromedii, Intellis Adaptivestim |
| Bioventus LLC | $848.68 | 2023 | Stimrouter Implantable Kit |
| Stimwave Technologies Incorporated | $730.85 | 2022 | |
| Averitas Pharma INC. | $131.46 | 2023 | Qutenza |
| Nevro Corp. | $125.54 | 2023 | Senza |
| Spr Therapeutics, INC | $119.89 | 2023 | Sprint Pns System |
| Saluda Medical Americas, INC. | $113.33 | 2023 | Evoke Scs |
| Nalu Medical, INC. | $85.40 | 2022 | |
| Curonix LLC | $81.29 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spinal Simplicity, LLC | $63.55 | 2023 | Ha Minuteman G3-R |
| Tersera Therapeutics LLC | $58.80 | 2022-2023 | Prialt |
| Relievant Medsystems, INC. | $40.97 | 2023 | Intracept |
| Acacia Pharma INC | $17.65 | 2021 | |
| Lundbeck LLC | $15.48 | 2023 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.